Coherus Oncology, Inc. (CHRS): M&A transaction — Coherus sells YUSIMRY (adalimumab-aqvh) to HKF for $40M upfront cash

Coherus Oncology, Inc.

Upfront all-cash consideration of $40M; closing occurred June 26, 2024.
HKF's subsidiary Meitheal will commercialize YUSIMRY in the U.S.
HKF assumes $17M in inventory purchase commitments; Coherus retains certain excluded assets/liabilities.
Divestiture aligns with Coherus' strategic focus on oncology; proceeds to bolster cash position.
Coherus retains oncology assets including LOQTORZI, UDENYCA franchise, and immuno-oncology pipeline.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Coherus Oncology, Inc. completed a disposition involving Hong Kong King-Friend Industrial Company Ltd. for upfront, all-cash consideration of $40.0 million (closed 2024-06-26).

Action: disposition
Counterparty: Hong Kong King-Friend Industrial Company Ltd.
Consideration: upfront, all-cash consideration of $40.0 million
Closing: 2024-06-26

Exact text from the filing

commitments, but not including certain identified excluded assets and excluded liabilities (collectively, the “YUSIMRY Disposition”) for upfront, all-cash consideration of $40.0 million paid on June 26, 2024. The Purchase Agreement also provides for indemnification rights related to breaches of each party’s representations, warranties, covenants and certain

View on SEC.gov

28 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-009526

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.